The FDA approved rucaparib for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Results from this study demonstrated that patients with cancer had a significantly lower detection rate of SARS-COV2 antibodies 15 days or later after COVID-19 symptoms and RT-PCR-positive test than healthcare workers.
This study found that fine particulate matter pollution was associated with mortality in pediatric, adolescent, and young adult patients with specific cancers, suggesting a need to enforce air quality policies.
Pomalidomide was approved for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative.
Researchers suggested that treatment-free remission may be successfully obtained with an effector-suppressor score which is calculated using absolute natural killer cells, FoxP3+ regulatory T cells, and monocytic myeloid-derived suppressor cells.
A phase II study presented at AACR found that the combination of atezolizumab plus cobimetinib improved cancer control in some patients with biliary tract cancer.
The phase II study found that nivolumab was well tolerated and demonstrated moderate efficacy with durable response in patients with refractory biliary tract cancer.
Researchers found that a high dose of CAR T-19 may be more effective than a low dose at inducing a complete response without excessive toxicity.
The oncology hematologist spoke about the guidelines she and her colleagues outlined regarding treating patients with hematologic malignancies during the COVID-19 pandemic.
The combination of tavo and pembrolizumab was associated with a higher than anticipated response rate in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes.